Figure 6. Effect of MCC-555 to the osteoblastic differentiation of 3-dimentional bmMSC cultures. Scaffolds which contained either control (shEV) or FASN-knockdown (shFASN) or FASN-knockdown plus MCC-555 (5 μM) co-treated (shFASN+M5) human bmMSCs were incubated under osteoblastic induction in the bioreactor, and retrieved at days 7, 14, and 21 for total RNA preparation. The levels of RUNX2 and ALP mRNAs were measured by RT-qPCR analyses. Normalized signals were compared to those of shEV of day 7 (to which a value of 1 was assigned). Data represent the mean ± S.D. from three experiments. One-way ANOVA plus Scheffe’s post hoc tests were used to analyze the differences. *, P<0.05 versus shEV cells of day 7.